替米沙坦联合非那雄胺治疗高血压并发良性前列腺增生的效果以及对血压、IPSS、Qmax、前列腺总体积和残余尿量的影响

doi:10.3969/j.issn.10073205.2018.04.003

河北医科大学学报

替米沙坦联合非那雄胺治疗高血压并发良性前列腺增生的效果以及对血压、IPSS、Qmax、前列腺总体积和残余尿量的影响

哈励逊国际和平医院老年病一科，河北衡水 053000

出版日期:2018-04-25 发布日期:2018-04-23
作者简介:李茹（1985-），女，河北衡水人，哈励逊国际和平医院主治医师，医学硕士，从事心脑血管疾病诊治研究。
基金资助:
衡水市科技计划项目（15018）

Effect of telmisartan combined finasteride on hypertension and benign prostatic hyperplasia and its effects on blood pressure, IPSS, Qmax, total prostate volume and residual urine volume

The First Department of Geriatric Medicine, Harrison International Peace Hospital, Hebei Province, Hengshui 053000, China

Online:2018-04-25 Published:2018-04-23

摘要/Abstract

摘要： ［摘要］〓
〖HTH〗目的〖HTSS〗〖KG*2〗观察替米沙坦联合非那雄胺治疗高血压并发良性前列腺增生的临床效果以及对血压水平、国际前列腺症状评分（international prostate symptom score,IPSS）、最大尿流率（qura of maximum,Qmax）、前列腺总体积和残余尿量的影响。
〖HTH〗方法〖HTSS〗〖KG*2〗将高血压并发良性前列腺增生患者108例随机分为A、B、C组各36例。A组给予替米沙坦治疗，B组给予非那雄胺治疗，C组给予替米沙坦联合非那雄胺治疗。随访1年，比较3组治疗效果，同时观察患者血压、IPSS、Qmax、前列腺总体积及残余尿量情况。
〖HTH〗结果〖HTSS〗〖KG*2〗治疗后3组SBP、DBP水平均明显低于治疗前（P＜005），3组间SBP、DBP、降血压效果及总有效率差异无统计学意义（P＞005）。治疗后3组前列腺体积均明显小于治疗前，B、C组前列腺体积小于A组，C组前列腺体积明显小于B组（P＜005）；3组前列腺增生治疗有效率差异无统计学意义（P＞005）。治疗后3组IPSS及残余尿量明显低于治疗前，Qmax明显高于治疗前，B、C组IPSS及残余尿量明显低于A组，Qmax高于A组， C组IPSS及残余尿量明显低于B组，Qmax高于B组（P＜005）。3组不良反应发生率差异无统计学意义（P＞005）。
〖HTH〗结论〖HTSS〗〖KG*2〗替米沙坦联合非那雄胺治疗高血压并发良性前列腺增生效果较好，能改善IPSS，增加Qmax，降低残余尿量，且不良反应少。

关键词: 高血压, 前列腺增生, 替米沙坦, 非那雄胺

Abstract: ［Abstract］〓Objective〖HTSS〗〓To investigate the clinical efficacy of telmisartan combined with finasteride in treatment of hypertension patients with benign prostatic hyperplasia and on the level of blood pressure, the International Prostate Symptom Score(IPSS), maximum urinary flow rate(Qmax), total prostate volume and residual urine volume.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓The 108 patients with hypertension and benign prostatic hyperplasia were randomly divided into group A, B and C with 36 cases in each group. Group A was given telmisartan treatment, group B was treated with finasteride, and group C was given telmisartan combined finasteride treatment. After 1 years of followup, the treatment effect of the 3 groups was compared and the blood pressure, IPSS, Qmax, the total volume of the prostate and the residual urine volume were observed.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓The levels of SBP and DBP in three groups after treatment were significantly lower than those before treatment(P＜005). There was no significant difference in SBP and DBP levels, blood pressure lowering effect and total effective rate between the three groups(P＞005). The volume of prostate in group B and C was smaller than that in group A, and the volume of prostate in group C was significantly less than that in group B(P＜005). There was no significant difference in the effective rates of three groups of prostatic hyperplasia(P＞005). The IPSS and residual urine volume of the three groups after treatment were significantly lower than that before treatment, Qmax was significantly higher than that before treatment. IPSS and residual urine volume in group B and C was significantly lower than the group A, Qmax higher than the group A, IPSS and residual urine volume in group C was significantly lower than that of group B, and Qmax was higher than that of group B(P＜005). There was no significant difference in the incidence of adverse reactions among the three groups(P＞005).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓Telmisartan combined with finasteride treatment of hypertension associated with benign prostatic hyperplasia are better, which can improve the IPSS, increase Qmax, reduce residual urine output, and less adverse reactions.

Key words: hypertension； prostatic hyperplasia； telmisartan, finasteride

李〓茹，胡威威，陈丽曼，英俊岐. 替米沙坦联合非那雄胺治疗高血压并发良性前列腺增生的效果以及对血压、IPSS、Qmax、前列腺总体积和残余尿量的影响[J]. 河北医科大学学报, doi: 10.3969/j.issn.10073205.2018.04.003.

LI Ru, HU Weiwei, CHEN Liman, YING Junqi. Effect of telmisartan combined finasteride on hypertension and benign prostatic hyperplasia and its effects on blood pressure, IPSS, Qmax, total prostate volume and residual urine volume[J]. Journal of Hebei Medical University, doi: 10.3969/j.issn.10073205.2018.04.003.

[1]	赵夕琛, 靳育静, 孙晓薇, 朱铁虹. 西格列汀联合氯沙坦钾治疗糖尿病合并高血压的安全性、有效性分析[J]. 河北医科大学学报, 2022, 43(4): 397-401，428.
[2]	张红金, 顾金涛, 徐红梅. 老年H型高血压伴急性脑梗死患者外周血LP-PLA2、S100-β与病情严重程度及预后的关系分析 [J]. 河北医科大学学报, 2022, 43(12): 1378-1383.
[3]	张佳慧, 马红云, 秦娟. 基于PI3K/Akt通路沉默miR-26b对妊娠期高血压胎盘滋养细胞增殖、凋亡的影响[J]. 河北医科大学学报, 2021, 42(9): 1063-1067.
[4]	王婷婷（综述）, 李广平, 富华颖（审校）. 肺高血压与代谢综合征关系研究进展[J]. 河北医科大学学报, 2021, 42(4): 492-496.
[5]	刘秀叶, 郭琼梅, 王喜莲, 周长浩, 王莉. 盐酸右美托咪定在妊娠期高血压高龄产妇剖宫产围术期应用效果研究[J]. 河北医科大学学报, 2021, 42(11): 1317-1322.
[6]	马晓, 张红影, 李佳, 贾金海, 张瑶, 庞建民. 某高校新生颈围与血压水平的Logistic回归分析[J]. 河北医科大学学报, 2021, 42(11): 1336-1340.
[7]	黄国洲, 廖振南, 利文倩, 吴亮, 周传凯. 手术方式和小骨窗微创手术治疗时间的选择对高血压脑出血患者疗效及生活质量的影响[J]. 河北医科大学学报, 2021, 42(10): 1215-1220.
[8]	袁胜芳1，宋宁2*，王布1，马士民2，赵建清1. 红细胞分布宽度联合血清胱抑素C早期诊断慢性阻塞性肺疾病继发肺动脉高压的价值[J]. 河北医科大学学报, 2020, 41(6): 624-627,631.
[9]	阚金龙1，刘健2，国平英3，常学良3，齐进春3,安淑惠3*. 经尿道双极等离子前列腺剜除术与经尿道等离子前列腺切除术治疗前列腺增生症的疗效对比[J]. 河北医科大学学报, 2020, 41(5): 562-565.
[10]	孙彦杰1，汪雁1，张金佳1，齐冉1，吴琼2，王荣英1*. 三级医院全科医学科联合社区综合干预对高血压管理效果分析[J]. 河北医科大学学报, 2020, 41(4): 391-395.
[11]	崔照领1，李扬2，朱芳3，莫中福1，曹珍珍1，郭春霞4. 妊娠期高血压疾病对新生儿凝血功能、NSE及PCT水平的影响[J]. 河北医科大学学报, 2020, 41(3): 306-310.
[12]	杨海娟1，许泽辉1，张梦华2. HFOV叠加CMV联合西地那非、注射用牛肺表面活性剂治疗重度PPHN的效果[J]. 河北医科大学学报, 2020, 41(3): 315-318.
[13]	杨飞，肖纯. 高血压肥胖者血浆促动脉硬化指数与心血管疾病风险的相关性研究[J]. 河北医科大学学报, 2020, 41(2): 138-141.
[14]	张凤玉, 俞霁云, 陈明星, 王军, 丁昌平, 蔡逸婷. 腺病毒介导的p53消减基因对慢性低氧性肺动脉高压大鼠的影响[J]. 河北医科大学学报, 2020, 41(12): 1369-1373.
[15]	韩〓巍1，韩艳丛2*，邱拥华1，黄丽荣1，郑小鹏1，刘家荣1. 高血压合并左心室肥厚患者血清miRNA29a3p水平与心肌纤维化的相关性[J]. 河北医科大学学报, 2019, 40(7): 773-776,793.

替米沙坦联合非那雄胺治疗高血压并发良性前列腺增生的效果以及对血压、IPSS、Qmax、前列腺总体积和残余尿量的影响

Effect of telmisartan combined finasteride on hypertension and benign prostatic hyperplasia and its effects on blood pressure, IPSS, Qmax, total prostate volume and residual urine volume

HTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价